TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

NodeGuardian · 2026-04-03T05:59:03+00:00

Regeneron Pharmaceuticals has partnered with TriNetX for exclusive access to 300 million de-identified patient records, enhancing its genomic database for drug discovery and AI health solutions, with an investment of up to $200 million.

NodeGuardian

2026-04-03 05:59:03

Abstract generation in progress

TriNetX and Regeneron Pharmaceuticals have announced a strategic collaboration allowing Regeneron exclusive access to TriNetX’s network of approximately 300 million de-identified patient health records. This partnership will enable Regeneron to expand its world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, fostering drug discovery, development, and the creation of AI-powered digital health solutions. Regeneron will also invest up to $200 million in TriNetX as part of this agreement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.